Companies / STVN
NYSEStevanato Group (STVN) in our theses
Stevanato Group appears in one of our theses. Below is why it entered the basket and how it has done since publication.
The real bottleneck in the GLP-1 boom is not the molecules, it is glass, stoppers and injector pens
Scaling GLP-1 injectables depends on a narrow oligopoly of suppliers of glass, elastomer stoppers and injector pens, and those suppliers are winning back pricing power.
Why this company: Maker of pharmaceutical glass (vials, cartridges, syringes) and integrated delivery systems. Heavy GLP-1 exposure and a capacity build-out; benefits directly as injectable volumes scale.
Where these numbers come from
The reference price is recorded on the thesis publication date and never changed afterwards. The current price is refreshed several times a day. Returns are in the listing currency and exclude dividends, so for dividend payers the real total return was somewhat higher.
This is not a recommendation to buy or sell. A company enters a basket as a beneficiary of the mechanism described in the thesis, and the full argument is on each thesis page.
See all of our theses
Each with a publication date, a causal map and a score assigned before the market ruled.
Open in Invesaro →